EYEN - Eyenovia, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.2900
+0.0100 (+0.30%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.2800
Open3.2700
Bid3.2900 x 3000
Ask4.9900 x 800
Day's Range3.2500 - 3.3600
52 Week Range2.4000 - 6.9830
Volume38,194
Avg. Volume93,807
Market Cap56.261M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.9680
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.20
Trade prices are not sourced from all markets
  • GlobeNewswire

    Eyenovia to Participate in Multiple Upcoming Medical Meetings

    NEW YORK, Oct. 02, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • Do Insiders Own Lots Of Shares In Eyenovia, Inc. (NASDAQ:EYEN)?
    Simply Wall St.

    Do Insiders Own Lots Of Shares In Eyenovia, Inc. (NASDAQ:EYEN)?

    A look at the shareholders of Eyenovia, Inc. (NASDAQ:EYEN) can tell us which group is most powerful. Institutions will...

  • GlobeNewswire

    Eyenovia to Present at Two Upcoming Investor Conferences

    NEW YORK, Sept. 03, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • ACCESSWIRE

    Eyenovia, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Eyenovia, Inc. (NASDAQ: EYEN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30:PM Eastern ...

  • GlobeNewswire

    Eyenovia Announces Conference Call and Webcast for Second Quarter 2019 Financial Results

    NEW YORK, Aug. 06, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire

    Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase an additional 658,273 shares at the public offering price of $2.78 per share. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Eyenovia in the public offering increased to 5,046,763 shares and net proceeds to Eyenovia from the public offering, after deducting underwriting discounts and commissions and offering expenses payable by Eyenovia, increased to approximately $13.0 million.

  • GuruFocus.com

    Eyenovia Inc (EYEN) CEO Tsontcho Ianchulev Bought $650,000 of Shares

    CEO of Eyenovia Inc (30-Year Financial, Insider Trades) Tsontcho Ianchulev (insider trades) bought 233,813 shares of EYEN on 07/11/2019 at an average price of $2.78 a share. Continue reading...

  • GlobeNewswire

    Eyenovia, Inc. Announces Closing of Public Offering

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced the closing of its previously announced underwritten public offering of 4,388,490 shares of common stock, at a public offering price of $2.78 per share. The net proceeds to Eyenovia from the public offering, after deducting underwriting discounts and commission and offering expenses payable by Eyenovia, were approximately $11.2 million. Eyenovia intends to use the net proceeds from the public offering, together with other available funds, for the MicroProst and MicroPine clinical studies and for working capital and general corporate purposes.

  • Did Eyenovia, Inc. (NASDAQ:EYEN) Insiders Buy Up More Shares?
    Simply Wall St.

    Did Eyenovia, Inc. (NASDAQ:EYEN) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Eyenovia, Inc. Prices Public Offering of Common Stock

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced the pricing of an underwritten public offering of 4,388,490 shares of its common stock at a price to the public of $2.78 per share. In addition, Eyenovia has granted the underwriters a 30-day option to purchase up to 658,273 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Eyenovia from the public offering, before deducting underwriting discounts and commissions and offering expenses payable by Eyenovia, are expected to be approximately $12.2 million.

  • GlobeNewswire

    Eyenovia, Inc. Announces Proposed Public Offering of Common Stock

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Eyenovia intends to use the net proceeds from the public offering, together with other available funds, for the MicroProst and MicroPine clinical studies and for working capital and general corporate purposes. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-229365) that was declared effective by the Securities and Exchange Commission (the “SEC”) on February 12, 2019.

  • GlobeNewswire

    Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it has initiated its MicroPine Phase III program with the first patient enrolled in its CHAPERONE study. The CHAPERONE study is a U.S.-based, multi-center, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age. The study will investigate the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovia’s proprietary atropine topical micro-formulation delivered by the Optejet™ dispenser.

  • GlobeNewswire

    Eyenovia Reports First Quarter 2019 Financial Results

    NEW YORK, May 14, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • Introducing Eyenovia (NASDAQ:EYEN), The Stock That Dropped 33% In The Last Year
    Simply Wall St.

    Introducing Eyenovia (NASDAQ:EYEN), The Stock That Dropped 33% In The Last Year

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Eyenovia, Inc. (NASDAQ:EYEN) share price has gained som...

  • GlobeNewswire

    Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results

    NEW YORK, May 01, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire

    Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results

    NEW YORK, March 27, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire

    Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

    NEW YORK, March 13, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire

    Eyenovia to Participate in Two Upcoming Investor Conferences

    NEW YORK, March 04, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire

    Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from its second MicroStat Phase III study, called MIST-2. The study examined the safety and efficacy of the Company’s first-in-class, MicroStat fixed-combination formulation, with target markets including the estimated 80 million annual pharmacologic mydriasis market in the United States. The MIST-2 study was a U.S.-based, multi-center, randomized, double-masked, superiority trial that enrolled 70 subjects, in whom both eyes were treated on separate days with Eyenovia's proprietary MicroStat fixed combination formulation of phenylephrine 2.5% and tropicamide 1%.

  • GlobeNewswire

    Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering

    NEW YORK, Feb. 13, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.

  • GlobeNewswire

    Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia

    Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate the CHAPERONE study - the Company's Phase III registration trial of MicroPine to reduce the progression of myopia in children. Currently, there are no FDA-approved therapies to slow the progression of myopia, a condition that, if uncontrolled, can in some cases be associated with major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment.

  • ACCESSWIRE

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / In January, the trend in biotech stocks appeared to be on a positive sloping trajectory as the IBB capped off its strongest month in almost a year. Below ...

  • ACCESSWIRE

    Biotechs Investors Are Flocking To

    HENDERSON, NV / ACCESSWIRE / January 31, 2019 / Below are a few biotechnology stocks seeing a growing amount of investor interest which is the precursor for long term bull runs. One company who's on the ...

  • ACCESSWIRE

    4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)

    With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.